bnz132-1-40
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT03046459)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2ANTAGONIST
IL2 antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bnz132-1-40
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03239392 | Phase 1/Phase 2 (Phase 2) | Jan 23, 2018 | Bioniz Therapeutics |
| NCT03239379 | Phase 1 | Oct 30, 2017 | Bioniz Therapeutics, Celerion |
| NCT03046459 | Phase 1 | Nov 1, 2016 | Bioniz Therapeutics, Celerion |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bioniz Therapeutics | For profit | 3 | 3 | 2 | 2016 |
| Celerion | For profit | 2 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1